Se espera que el mercado mundial de edición genómica crezca a una tasa anual compuesta de más del 18,5 % entre 2021 y 2029. Se espera que alcance más de 14 560 millones de dólares en 2029, frente a los 3250 millones de dólares de 2020.
El mercado de edición genómica se refiere al mercado de tecnologías y productos relacionados con la edición genómica, un método preciso para realizar cambios específicos en el ADN de una célula u organismo. Las técnicas de edición genómica, como CRISPR -Cas9, TALEN y nucleasas de dedos de zinc, permiten a los científicos modificar la secuencia de ADN de los organismos con una precisión sin precedentes. Estas tecnologías tienen aplicaciones de amplio alcance en varios campos, incluidos la agricultura, la atención médica, la biotecnología y la investigación. En la agricultura, la edición genómica se puede utilizar para desarrollar cultivos con un rendimiento mejorado, resistencia a las enfermedades y tolerancia al estrés ambiental. En la atención médica, la edición genómica es prometedora para el tratamiento de trastornos genéticos, cáncer y enfermedades infecciosas al corregir o modificar los genes que causan enfermedades.
La expansión del mercado se debe principalmente a la creciente demanda de genes sintéticos y a la adopción generalizada de la tecnología de edición genómica CRISPR en diversos sectores de la biotecnología. Además, se espera que el crecimiento previsto esté impulsado por el aumento de la financiación gubernamental, la mayor producción de cultivos modificados genéticamente y un aumento de los proyectos genómicos.
El crecimiento del mercado se ve impulsado por las regulaciones gubernamentales favorables en materia de biología sintética, la mayor demanda de genes y células modificados genéticamente y el aumento de las inversiones de los organismos gubernamentales y las grandes corporaciones. Además, el descubrimiento y la aplicación de técnicas de edición genética no convencionales con fines terapéuticos representan un avance significativo en la terapia génica y la biología molecular, lo que contribuye aún más a la expansión del mercado.
Además, la disponibilidad de sistemas de terapia génica fáciles de usar, los avances en ingeniería genómica y el potencial de la terapia génica para facilitar análisis rápidos de la función genética en todo el genoma contribuyen al crecimiento del mercado durante el período de pronóstico.
On the basis of technology type, the global genome editing market has been segmented as – CRISPR, Talen, ZFN, and other genome editing or genetic editing technologies. CRISPR is a powerful tool for editing genomes, denotation it allows researchers to easily modify DNA sequences and change gene function. It has many potential applications, including amending genetic defects, treating and preventing the spread of diseases, and improving the growth and resilience of crops.
Talen can be used to edit genomes by encouraging double-strand breaks (DSB), which cells respond to with repair mechanisms. Non-homologous end joining (NHEJ) directly ligates DNA from either side of a double-strand break where there is very slight or no sequence overlap for annealing. Zinc Finger Nucleases (ZFNs) are a class of engineered DNA-binding proteins that enable targeted editing of the genome by creating double-strand breakdowns in DNA at user-specified locations. The other technologies category includes antisense technology and mega nucleases.
Based on application, the genome editing market is divided into five segments, gene therapy, disease models, functional genomics, knockdown/activation and other applications. Genetic engineers have developed genetic recombination techniques or genome editing techniques to manipulate gene sequences in plants, animals and other organisms to express specific traits. Applications for genetic editing are increasing as engineers and scientists work together to identify the locations and functions of specific genes in the DNA sequence of various organisms.
A laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. This method can be used to find changes in areas of the genome. These changes may help scientists understand how specific diseases form. Functional genomics involves learning the expression and function of the genome. Genomics can also comprise the investigation of interactions between genes and between genes and the environment.
End user segment of the global genome editing market includes academic & government research institutes, biotechnology & pharmaceutical companies, contract research organizations, and other end users. Biotechnology and pharmaceutical companies are one of the major end users of the genome editing market. These companies are incorporating numerous CRISPR gene editing products and services for the treatment and screening of genetic disorders. Gene therapy holds potential for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.
Abcam, Inc., is one of the emerging players in the CRISPR gene editing market. The global life sciences company develops biological reagents and tools required in drug discovery, basic research, diagnostics, and other fields and applications. The company offers research-based only proteomic tools, antibodies, protein binding reagents, and immunoassays to researchers and scientists in academic institutes, biotechnology, diagnostics, and pharmaceuticals companies for studying biological pathways critical in scientific research, drug discovery, and diagnostics.
Applied StemCell, Inc., headquartered in California, US, is one of the emerging private players in the gene editing market. The company develops gene modification technologies enabling stem cell and genome editing to augment revolutionary biomedical and industrial research and applications. The company’s competitors that cater to the CRISPR gene editing market include System Biosciences LLC, Horizon Discovery Group PLC, Takara Bio, GeneCopoeia, Inc., and Cellecta, Inc., among others.
The genome editing market by region includes North America, Europe, Asia-Pacific (APAC), South America, and Middle East & Africa (MEA). The North America region is currently dominating the global genome editing market. Several conglomerate and small-medium enterprises are focused on collaborating with each other and other distributing channels to expand their global reach by developing more cost-effective and advanced products is consequentially promoting the growth of the global genome editing market.
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.